Advertisement

Amino Acids

, Volume 40, Issue 3, pp 1003–1013 | Cite as

ESM-1 silencing decreased cell survival, migration, and invasion and modulated cell cycle progression in hepatocellular carcinoma

  • Yun Hee Kang
  • Na Young Ji
  • Chung Il Lee
  • Hee Gu Lee
  • Jae Wha Kim
  • Young IL Yeom
  • Dae Ghon Kim
  • Seung Kew Yoon
  • Jong Wan Kim
  • Pil Je Park
  • Eun Young SongEmail author
Original Article

Abstract

Endothelial cell-specific molecule-1 (ESM-1) is a secretory proteoglycan comprising a mature polypeptide of 165 amino acids and a single dermatan sulfate. The aim of this study was to evaluate endothelial cell-specific molecule-1 (ESM-1) as a hepatocellular carcinoma (HCC) marker and to analyze the effect of ESM-1 gene silencing in hepatocellular carcinoma cells. RT-PCR and Western Blot analysis revealed overexpression of ESM-1 in human HCC liver tissue and in serum from patients with HCC. Sandwich ELISA assay was used for quantitative analysis of ESM-1 in serum. Levels of ESM-1 were significantly elevated in the serum of patients with HCC (n = 40) as compared to serum from patients with hepatitis (AH, n = 40; CH, n = 39) or liver cirrhosis (n = 40) or from healthy subjects (n = 40). The accuracy of ESM-1 for HCC was higher than that of α-fetoprotein (AFP) according to ROC curve analysis. Expression of ESM-1 siRNA decreased cell survival through the inhibition of NF-κB pathway and induced cell cycle arrest by PTEN induction resulting in the inhibition of cyclin D1 in SK-Hep1 cells. Furthermore, ESM-1 silencing inhibited cell migration and invasion of SK-Hep1 cells. This study demonstrates that ESM-1 as a potential tumor marker is overexpressed in most tissues and serum in the presence of HCC and is involved with cell survival, cell cycle progression, migration, and invasion of hepatocellular carcinoma cells. Based on our results, we suggest that ESM-1 or a combination of ESM-1 and AFP is useful markers for diagnosis of HCC and ESM-1 may be useful therapeutic target of hepatocellular carcinoma.

Keywords

ESM-1 Hepatocellular carcinoma Diagnostic marker Cell cycle Cell migration 

Notes

Acknowledgments

We thank the staff of the Kangnam St. Mary’s Hospital (Seoul, Republic of Korea) for supplying serum samples and BioInfra Inc. (Seoul, Korea) for analysis of AFP. This work was supported by Basic Science Research Program through the National Research Foundation of Korea (NRF, 20100011583) and a KRIBB Research Initiative fund from the Ministry of Education, Science and Technology (MEST) provided by the Korean Government. No potential conflicts of interest were disclosed.

References

  1. Aitkenhead M, Wang SJ, Nakatsu MN, Mestas J, Heard C, Hughes CC (2002) Identification of endothelial cell genes expressed in an in vitro model of angiogenesis: induction of ESM-1, (beta)ig-h3, and NrCAM. Microvasc Res 63:159–171CrossRefPubMedGoogle Scholar
  2. Bechard D, Meignin V, Scherpereel A, Oudin S, Kervoaze G, Bertheau P, Janin A, Tonnel A, Lassalle P (2000) Characterization of the secreted form of endothelial-cell-specific molecule 1 by specific monoclonal antibodies. J Vasc Res 37:417–425CrossRefPubMedGoogle Scholar
  3. Filep JG (2006) Endocan or endothelial cell-specific molecule-1: a novel prognostic marker of sepsis? Crit Care Med 34:574–575CrossRefPubMedGoogle Scholar
  4. Furnari FB, Huang HJ, Cavenee WK (1998) The phosphoinositol phosphatase activity of PTEN mediates a serum-sensitive G1 growth arrest in glioma cells. Cancer Res 58:5002–5008PubMedGoogle Scholar
  5. Gomaa AI, Khan SA, Toledano MB, Waked I, Taylor-Robinson SD (2008) Hepatocellular carcinoma: epidemiology, risk factors and pathogenesis. World J Gastroenterol 14:4300–4308CrossRefPubMedGoogle Scholar
  6. Grigoriu BD, Depontieu F, Scherpereel A, Gourcerol D, Devos P, Ouatas T, Lafitte JJ, Copin MC, Tonnel AB, Lassalle P (2006) Endocan expression and relationship with survival in human non-small cell lung cancer. Clin Cancer Res 12:4575–4582CrossRefPubMedGoogle Scholar
  7. Huang GW, Tao YM, Ding X (2009) Endocan expression correlated with poor survival in human hepatocellular carcinoma. Dig Dis Sci 54:389–394CrossRefPubMedGoogle Scholar
  8. Jimenez C, Portela RA, Mellado M, Rodriguez-Frade JM, Collard J, Serrano A, Martinez AC, Avila J, Carrera AC (2000) Role of the PI3 K regulatory subunit in the control of actin organization and cell migration. J Cell Biol 151:249–262CrossRefPubMedGoogle Scholar
  9. Lassalle P, Molet S, Janin A, Heyden JV, Tavernier J, Fiers W, Devos R, Tonnel AB (1996) ESM-1 is a novel human endothelial cell-specific molecule expressed in lung and regulated by cytokines. J Biol Chem 271:20458–20464CrossRefPubMedGoogle Scholar
  10. Lauffenburger DA, Horwitz AF (1996) Cell migration: a physically integrated molecular process. Cell 84:359–369CrossRefPubMedGoogle Scholar
  11. Li DM, Sun H (1998) PTEN/MMAC1/TEP1 suppresses the tumorigenicity and induces G1 cell cycle arrest in human glioblastoma cells. Proc Natl Acad Sci USA 95:15406–15411CrossRefPubMedGoogle Scholar
  12. Lopez JB (2005) Recent developments in the first detection of hepatocellular carcinoma. Clin Biochem Rev 26:65–79PubMedGoogle Scholar
  13. Paramio JM, Navarro M, Segrelles C, Gomez-Casero E, Jorcano JL (1999) PTEN tumour suppressor is linked to the cell cycle control through the retinoblastoma protein. Oncogene 18:7462–7468CrossRefPubMedGoogle Scholar
  14. Perey L, Benhattar J, Peters R, Jaunin P, Leyvraz S (2001) High tumour contamination of leukaphereses in patients with small cell carcinoma of the lung: a comparison of immunocytochemistry and RT-PCR. Br J Cancer 85:1713–1721CrossRefPubMedGoogle Scholar
  15. Persad S, Troussard AA, McPhee TR, Mulholland DJ, Dedhar S (2001) Tumor suppressor PTEN inhibits nuclear accumulation of beta-catenin and T cell/lymphoid enhancer factor 1-mediated transcriptional activation. J Cell Biol 153:1161–1174CrossRefPubMedGoogle Scholar
  16. Radu A, Neubauer V, Akagi T, Hanafusa H, Georgescu MM (2003) PTEN induces cell cycle arrest by decreasing the level and nuclear localization of cyclin D1. Mol Cell Biol 23:6139–6149CrossRefPubMedGoogle Scholar
  17. Reinhart K, Meisner M, Brunkhorst FM (2006) Markers for sepsis diagnosis: what is useful? Crit Care Clin 22:503–519 ix-xCrossRefPubMedGoogle Scholar
  18. Rennel E, Mellberg S, Dimberg A, Petersson L, Botling J, Ameur A, Westholm JO, Komorowski J, Lassalle P, Cross MJ, Gerwins P (2007) Endocan is a VEGF-A and PI3 K regulated gene with increased expression in human renal cancer. Exp Cell Res 313:1285–1294CrossRefPubMedGoogle Scholar
  19. Sarrazin S, Adam E, Lyon M, Depontieu F, Motte V, Landolfi C, Lortat-Jacob H, Bechard D, Lassalle P, Delehedde M (2006) Endocan or endothelial cell specific molecule-1 (ESM-1): a potential novel endothelial cell marker and a new target for cancer therapy. Biochim Biophys Acta 1765:25–37PubMedGoogle Scholar
  20. Scherpereel A, Gentina T, Grigoriu B, Senechal S, Janin A, Tsicopoulos A, Plenat F, Bechard D, Tonnel AB, Lassalle P (2003) Overexpression of endocan induces tumor formation. Cancer Res 63:6084–6089PubMedGoogle Scholar
  21. Scherpereel A, Depontieu F, Grigoriu B, Cavestri B, Tsicopoulos A, Gentina T, Jourdain M, Pugin J, Tonnel AB, Lassalle P (2006) Endocan, a new endothelial marker in human sepsis. Crit Care Med 34:532–537CrossRefPubMedGoogle Scholar
  22. Sherr CJ, Roberts JM (1999) CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 13:1501–1512CrossRefPubMedGoogle Scholar
  23. Sun H, Lesche R, Li DM, Liliental J, Zhang H, Gao J, Gavrilova N, Mueller B, Liu X, Wu H (1999) PTEN modulates cell cycle progression and cell survival by regulating phosphatidylinositol 3,4,5,-trisphosphate and Akt/protein kinase B signaling pathway. Proc Natl Acad Sci USA 96:6199–6204CrossRefPubMedGoogle Scholar
  24. Weng LP, Brown JL, Eng C (2001) PTEN coordinates G(1) arrest by down-regulating cyclin D1 via its protein phosphatase activity and up-regulating p27 via its lipid phosphatase activity in a breast cancer model. Hum Mol Genet 10:599–604CrossRefPubMedGoogle Scholar
  25. Yuen MF, Lai CL (2005) Serological markers of liver cancer. Best Pract Res Clin Gastroenterol 19:91–99CrossRefPubMedGoogle Scholar
  26. Zhou L, Liu J, Luo F (2006) Serum tumor markers for detection of hepatocellular carcinoma. World J Gastroenterol 12:1175–1181PubMedGoogle Scholar
  27. Zhu X, Kwon CH, Schlosshauer PW, Ellenson LH, Baker SJ (2001) PTEN induces G(1) cell cycle arrest and decreases cyclin D3 levels in endometrial carcinoma cells. Cancer Res 61:4569–4575PubMedGoogle Scholar
  28. Zou AP, Cheng G, Pi YQ, Wang WH, Yu SB, Wang DX (1989) The role of lipoxygenase and cyclooxygenase metabolites in acute hypoxic pulmonary vasoconstriction in piglets. J Tongji Med Univ 9:239–243CrossRefPubMedGoogle Scholar
  29. Zuo L, Zhang SM, Hu RL, Zhu HQ, Zhou Q, Gui SY, Wu Q, Wang Y (2008) Correlation between expression and differentiation of endocan in colorectal cancer. World J Gastroenterol 14:4562–4568CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  • Yun Hee Kang
    • 1
  • Na Young Ji
    • 1
  • Chung Il Lee
    • 1
  • Hee Gu Lee
    • 1
  • Jae Wha Kim
    • 1
  • Young IL Yeom
    • 1
  • Dae Ghon Kim
    • 2
  • Seung Kew Yoon
    • 3
  • Jong Wan Kim
    • 4
  • Pil Je Park
    • 5
  • Eun Young Song
    • 1
    Email author
  1. 1.Medical Genomics Research Center, KRIBBDaejeonKorea
  2. 2.Department of Internal MedicineChonbuk National University Medical School and HospitalJeonjuKorea
  3. 3.Department of Internal Medicine, College of MedicineThe Catholic University of KoreaSeoulKorea
  4. 4.Department of Laboratory MedicineDankook University School of MedicineCheonanKorea
  5. 5.BioInfra. Inc.SeoulKorea

Personalised recommendations